AI tool for predicting outcomes in bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an artificial-intelligence (AI) tool that uses your bladder cancer details to help predict outcomes. It may help doctors better choose the next treatment after bladder cancer is found early (non-muscle invasive).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have intermediate- or high-risk non-muscle invasive bladder cancer from pathology after TURBT
- Your bladder cancer is at stage T1 (not T2 or higher)
- You received bladder treatments inside the bladder (BCG, mitomycin C, or gemcitabine/docetaxel) within 6 months
- The study needs enough removed-tissue samples from your TURBT to use
- You are 18 or older and can read/speak English or Spanish and sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an immunotherapy drug (toripalimab) alone or followed by medication placed directly into the bladder (gemcitabine and mitomycin C) for people with high-risk bladder cancer that has not spread into the muscle wall and that has not responded to or couldn't be handled with BCG therapy. The goal is to see which approach works better.
This Phase 2 trial tests TARA-002 given directly into the bladder to treat high-grade non–muscle-invasive bladder cancer with active disease. It may help patients who have not previously responded to, or have not received, BCG treatment in the recent past.
This trial tests whether artificial intelligence (AI) can help guide surgeons during a procedure called TURBT to remove early-stage bladder cancer. The goal is to see if this technology improves the removal of cancer while potentially reducing risks.
This study tests an artificial-intelligence (AI) system during real-time bladder evaluation to better spot bladder tumors. It may help your care team find tumors more accurately during diagnosis or follow-up.
This study tests an artificial intelligence tool designed to predict how patients will recover after bladder cancer surgery. The AI analyzes existing medical information to help doctors better understand which patients might face complications based on their other health conditions.
This trial is testing an artificial intelligence (AI) system that helps doctors diagnose and treat urological conditions like urinary stones, prostate cancer, or bladder cancer. It looks at your medical records, scans, and surgical videos to improve care.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.